RxDoctor Payments DataLook up a doctor →

Daron Street, MD

Gynecologic Oncology · Tulsa, OKNPI 1083656912

Payments from drug & device makers

$277,543in general payments, 2019–2025

Across 304 payments — averaging $912.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Trillium Therapeutics USA, LLC$189K
  • Coherus Oncology, Inc.$23K
  • Merck$18K
  • Pfizer$17K
  • GSK$5K
  • Intuitive Surgical$5K
  • plus $21K from 47 others

What the payments were for

  • Consulting fees$14,51427%
  • Speaking & faculty fees$23,46343%
  • Travel & lodging$1,4243%
  • Food & beverage$10,90620%
  • Education$4,2178%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$277,543 in reported general payments places this provider in the 65th percentile of 21 gynecologic oncology providers in Oklahoma.

See all gynecologic oncology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$2,369,052
Medicare patients
388
Services billed
93,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate11$203,922
EliquisApixaban12$7,149
Estradiol36$1,572
Megestrol Acetate25$1,518
Gabapentin43$665
Oxycodone Hcl47$626
Clobetasol Propionate13$491
Lidocaine-PrilocaineLidocaine/Prilocaine26$403
Ondansetron Hcl18$346
Sertraline Hcl26$260
Dexamethasone16$230
Prochlorperazine Maleate21$212
Medroxyprogesterone Acetate29$180
Ondansetron OdtOndansetron15$173
Nystatin14$170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$5,422$203,92211 claims
PfizerEliquis$17,140$7,14912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 21 gynecologic oncology providers in Oklahoma.

Other gynecologic oncology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →